Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biotechnology pioneer developing tumor microenvironment-activated immunotherapies. This page aggregates all material news and regulatory disclosures about the company's innovative TMAb™ platform and clinical programs.
Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, financial disclosures, and scientific developments. Our curated collection ensures efficient tracking of key milestones in Sensei's quest to create conditionally active cancer therapies.
The repository includes earnings reports, FDA communications, research collaborations, and peer-reviewed publication highlights. All content is vetted for relevance to SNSE's core focus on overcoming immune suppression in solid tumors through pH-sensitive antibody engineering.
Bookmark this page for structured access to Sensei's evolving pipeline updates and corporate announcements. Regularly refreshed content supports informed decision-making about this innovative player in next-generation immuno-oncology.
Sensei Biotherapeutics (NASDAQ: SNSE) announced preliminary preclinical data for SNS-101, an antibody targeting the VISTA immune checkpoint. Results indicate that SNS-101 effectively overcomes pharmacokinetic challenges and enhances anti-tumor effects when combined with anti-PD-1 antibodies. Additionally, SNS-101 shows a favorable pharmacokinetic profile, with a median half-life of approximately three weeks. Ongoing IND-enabling studies aim to evaluate SNS-101's potential for treatment in solid cancers, with an IND filing planned for the first half of 2023.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in two key investor conferences in September 2022, aimed at exploring the latest in immuno-oncology developments.
The conferences are:
- Citi’s 17th Annual Biopharma Conference (September 7-8, Boston, MA)
- Wells Fargo’s 2022 Healthcare Conference (September 7-9, Boston, MA)
Interested portfolio managers and analysts can arrange meetings with company management through their respective representatives.
Sensei Biotherapeutics (NASDAQ: SNSE) announced progress in its clinical programs, including pre-IND feedback from the FDA for SNS-101, an anti-VISTA antibody, expected to file an IND in the first half of 2023. The company will present new pharmacokinetic data in non-human primates in Q3 2022. The strong financial position, with cash equivalents of $123.7 million, supports operations through Q1 2025. Research and development expenses increased to $6.4 million due to higher headcount and inflation. The net loss was reported at $10.5 million for Q2 2022.
On June 1, 2022, Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Patrick Gallagher as Chief Business Officer. Gallagher, an experienced biotech executive, will leverage his nearly 20 years in the pharmaceutical and biotech sectors to enhance Sensei's strategic initiatives. His past roles include significant contributions to various reputable companies and investment banking firms. This leadership change is expected to strengthen the company's position during critical phases of program advancements.
Sensei Biotherapeutics, a leader in immunotherapy, announced that CEO John Celebi will present at the Jefferies Healthcare Conference on June 8, 2022, at 3:00 p.m. ET, both in-person and virtually in New York, NY. Investors can access a live webcast of the presentation on the company's website, with a replay available for 90 days afterward. Sensei focuses on developing innovative cancer therapies, utilizing its TMAb™ and ImmunoPhage™ platforms. Their lead therapeutic candidate, SNS-101, targets the VISTA checkpoint to enhance T cell activity in the tumor microenvironment.
Sensei Biotherapeutics (SNSE) reported Q1 2022 financial results, highlighting a net loss of $12.4 million, up from $8.0 million in Q1 2021. The company's cash reserves stood at $136.2 million, sufficient to fund operations through Q1 2025. Progress on the TMAb™ platform includes promising preclinical data for SNS-101, an anti-VISTA antibody targeting solid tumors, which showed selective binding in low pH environments. The firm also anticipates submitting an IND for SNS-101 in the first half of 2023 following successful GMP manufacturing initiation.
Sensei Biotherapeutics (NASDAQ: SNSE) announced significant advancements in its pipeline with the initiation of new therapeutic programs, including SNS-101, an anti-VISTA antibody. The company reported a strong cash position of $147.6 million as of December 31, 2021, providing a runway into the first half of 2024. Additionally, the management team was strengthened with key appointments. SNS-101 shows promise against the VISTA immune checkpoint, vital for overcoming challenges in cancer treatment.
Sensei Biotherapeutics (NASDAQ: SNSE) has appointed William Ringo as chair of its Board of Directors, enhancing leadership during a pivotal phase for the company. Ringo, with over 40 years in the pharmaceutical and biotech industries, brings extensive experience from Pfizer and Eli Lilly. His leadership is expected to support Sensei's objectives in developing innovative cancer therapies, particularly through its unique TMAb™ and ImmunoPhage™ platforms. The company is focused on advancing treatments such as SNS-101 and SNS-401-NG.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Company leaders, including John Celebi and Erin Colgan, will present virtually on March 15 at 10:40 am ET. A replay of the presentation will be available for 90 days on their website. Sensei Biotherapeutics focuses on developing next-generation cancer immunotherapies, utilizing its innovative TMAb and ImmunoPhage platforms for personalized treatment options.
BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in Citi's 2022 Immuno-Oncology Summit. Dr. Robert Pierce, Chief R&D Officer, will engage in a fireside chat on February 16, 2022, at 2:30 PM ET. The event will be webcast live, with a replay available for 90 days on the company's website. Sensei Biotherapeutics specializes in next-generation immunotherapies for cancer, utilizing its TMAb™ platform for antibody development and ImmunoPhage™ platform to create personalized treatments for various cancers.
FAQ
What is the current stock price of Sensei Biotherapeutics (SNSE)?
What is the market cap of Sensei Biotherapeutics (SNSE)?
